

(12) PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. **AU 199726334 B2**
(10) Patent No. **727662**

(54) Title
Peptides with antiproliferative properties

(51)⁶ International Patent Classification(s)
C07K 001/00

(21) Application No: 199726334 (22) Application Date: 1997.03.26

(87) WIPO No: W097/35873

(30) Priority Data

| (31) Number | (32) Date | (33) Country |
|-------------|------------|--------------|
| 19611939 | 1996.03.26 | DE |
| 19653445 | 1996.12.20 | DE |

(43) Publication Date : 1997.10.17
(43) Publication Journal Date : 1997.12.11
(44) Accepted Journal Date : 2000.12.21

(71) Applicant(s)
Razvan, T. Radulescu

(72) Inventor(s)
Razvan, T. Radulescu

(74) Agent/Attorney
DAVIES COLLISON CAVE, 1 Little Collins Street, MELBOURNE VIC 3000

(56) Related Art
DE 4237129
RADULESCU, R.T. BIOCHEM BIOPHYS. RES. COMM. 246,1, PP97-102
(1995)

OPI DATE 17/10/97 APPLN. ID 26334/97
AOJP DATE 11/12/97 PCT NUMBER PCT/DE97/00643



AU9726334

| | | | |
|--|--|--|---|
| (51) Internationale Patentklassifikation ⁶ : C07K 1/00 | | A2 | (11) Internationale Veröffentlichungsnummer: WO 97/35873 |
| SEARCH QUALITY ASSURANCE | | (43) Internationales Veröffentlichungsdatum: | 2. Oktober 1997 (02.10.97) |
| (21) Internationales Aktenzeichen: PCT/DE97/00643 | | (81) Bestimmungsstaaten: AL, AM, AU, BB, BG, BR, CA, CN, CZ, EE, GE, HU, IS, JP, KG, KP, KR, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, ARIPO Patent (GH, KE, LS, MW, SD, SZ, UG), eurasisches Patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), europäisches Patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI Patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). | |
| (22) Internationales Anmeldedatum: 26. März 1997 (26.03.97) | | Veröffentlicht <i>Ohne internationalen Recherchenbericht und erneut zu veröffentlichen nach Erhalt des Berichts.</i> | |
| (30) Prioritätsdaten: 196 11 939.1 26. März 1996 (26.03.96) DE 196 53 445.3 20. December 1996 (20.12.96) DE | | | |
| (71)(72) Anmelder und Erfinder: RADULESCU, Razvan, T. [DE/DE]; Gardinistrasse 47, D-81375 München (DE). | | | |
| (74) Anwalt: PFENNING MEINIG UND PARTNER; Mozartstrasse 17, D-80336 München (DE). | | | |
| (54) Title: PEPTIDES WITH ANTIPROLIFERATIVE PROPERTIES | | | |
| (54) Bezeichnung: PEPTIDE MIT ANTIPROLIFERATIVEN EIGENSCHAFTEN | | | |
| (57) Abstract | | | |
| <p>The present invention relates to antiproliferative peptides which are derived from a tumour-suppressor protein and bond to growth factor or growth factor-receptor segments. The invention also relates to nucleic acids (DNAs/RNAs) which code for these peptides and structurally homologous peptide nucleic acids and pharmaceutical compositions containing such peptides. The invention can be used in biotechnology, molecular biology, bioinformatics and in diagnosis and therapy of hyperproliferative disorders, in particular cancer and atherosclerosis.</p> | | | |
| (57) Zusammenfassung | | | |
| <p>Die vorliegende Erfindung betrifft antiproliferative Peptide, die sich von einem Tumorsuppressorprotein ableiten und an Wachstumsfaktor- oder Wachstumsfaktor-Rezeptor-Segmente binden. Weiter betrifft die Erfindung Nukleinsäuren (DNAs/RNAs), die für diese Peptide kodieren, sowie dazu strukturell homologe Peptidnukleinsäuren und pharmazeutische Zusammensetzungen, die die Peptide enthalten. Die Erfindung findet Verwendung in der Biotechnologie, der Molekularbiologie, der Bioinformatik und der Diagnose und Therapie von hyperproliferativen Erkrankungen, insbesondere von Krebs und der Atherosklerose.</p> | | | |

Summary

The present invention relates to antiproliferative peptides which are derived from a tumor suppressor protein and bind to growth factor segments or growth factor receptor segments. The invention also relates to nucleic acids (DNAs/RNAs) which code for these peptides and structurally homologous peptide nucleic acids and pharmaceutical compositions containing such peptides. The invention can be used in biotechnology, molecular biology, bioinformatics and in the diagnosis and therapy of hyperproliferative disorders, in particular cancer and atherosclerosis.



Peptides having antiproliferative properties

The present invention pertains to peptides having antiproliferative properties, nucleic acids (DNA/RNA) coding for said peptides, peptide nucleic acids that are structurally homologous to said nucleic acids and the use of said peptides, said nucleic acids, said peptide nucleic acids and/or pharmaceutical compositions thereof in biotechnology, in molecular biology, bioinformatics, as well as the diagnosis and therapy of hyperproliferative diseases, particularly cancer and atherosclerosis.

In oncology there are a variety of different treatment regimens primarily based on surgical procedures, chemotherapy or radiation therapy. However, these methods have not provided the desired results in cancer therapy. According to current statistics in the United States of America every third person living there develops cancer and every fifth person is going to die therefrom. This number is likely to apply to all industrialized nations all over the world and has not significantly changed for more than a decade. Moreover, it is to be noted that the efficacy of treating cancer has not substantially improved during the past twenty years since the five-year survival rate has essentially stayed the same for most cancer types (R.N. Proctor "The Sciences", March/April 1995, pp. 20-24).

Therefore, the objective of the present invention is to provide a means to inhibit the growth of a variety of different types of cancer eventually resulting in a regression of the tumors.

This objective is achieved by a peptide according to claim 1, by a nucleic acid (DNA/RNA) according to claim 13, by a peptide nucleic acid according to claim 16, by a pharmaceutical composition according to claim 17 and by the use of said peptides according to claim 20, by the use of the DNA/RNA according to claim 22, by the use of the peptide nucleic acid according to claim 23 and by the use of a pharmaceutical composition according to claim 21. Preferred embodiments are illustrated in the dependent claims.

The present inventor has found a promising approach in the treatment of cancer which is to utilize specific peptides that block substances causing cancer, particularly oncogenic proteins. The peptides of the present invention are characterized by a short sequence length which renders them economical in terms of their synthesis. Moreover, they are



able to efficiently penetrate cells and, as a result, are capable of neutralizing intracellular proteins that promote the development of cancer.

It has previously been found that in a variety of cancer types tumor suppressor genes are deleted or mutated which in turn results in an insufficient provision of the corresponding gene products. This finally leads to the development of cancer (A.G. Knudson, Proc. Natl. Acad. Sci., USA (1993), vol. 90, pp 10914-10921; A.J. Levine, Sci. Am. "Science & Medicine", Jan./Feb. 1995, pp. 28-37).

Defects in tumor suppressor proteins, such as RB1, also seem to be important for the pathogenesis of other hyperproliferative diseases, e.g. atherosclerosis. The present inventor has found that it is sufficient to introduce parts of a tumor suppressor protein into cells in order to block growth factors that accelerate the uncontrolled growth of cells. It is not possible to introduce the entire tumor suppressor protein since such a protein is too long and is in most cases is subject to proteolytic degradation, thus preventing the protein from exerting its effect. On the other hand, if only parts of tumor suppressor proteins are utilized, said parts are too rapidly degraded as well, i.e. they are not sufficiently stable.

The peptides according to the present invention are therefore synthetic fusion polypeptides consisting of the components (A) and (B), wherein these components are connected to each other as AB or BA. The first component (A) comprises an effective part of a tumor suppressor protein - in such a form as first found by the inventor - or is hydropathically homologous thereto. The second component (B) comprises a sequence that stabilizes the first component (A). According to the invention the peptide of the present invention binds to a growth factor or a growth factor receptor, preferably to the sequence LXCXE therein, more preferably to the LXCXE sequence in insulin, i.e. to LVCGE (Radulescu et al., Biochemical and Biophysical Research Communications 1995, vol. 206, pp. 97-102). Since the growth factors IGF-1 and IGF-2 comprise the sequence FVCGD, which sequence is hydropathically homologous to the segment LVCGE in insulin (R. Radulescu & C. Wendtner, J. Mol. Recognition 1992, vol. 5, pp. 133-137) the peptide of the invention binds to IGF-1 and IGF-2 as well.

The term "hydropathically homologous" is used herein according to the teaching of Kyte and Doolittle (J. Kyte & R.F. Doolittle, J. Mol. Biol. 1982, vol. 157, pp. 105-132) and J.E. Blalock and Smith, E.M. (Biochemical and Biophysical Research Communications, Vol. 121, no. 1, pp. 203-207 (1984)).



The component (A) is further characterized by the fact that it is hydrophatically complementary to a fragment of a growth factor or of a growth factor receptor according to the complementary peptide theory (J.E. Blalock, Trends in Biotechnology, vol. 8, pp. 140-144, June 1990) or according to the three-dimensional configuration, respectively. Examples for growth factors are: insulin, IGF-1, IGF-2, EGF, FGF, angiogenin, NGF and PDGF.

According to the present invention the effective regions for component (A) of the peptide according to the present invention may be derived from the following tumor suppressor gene products: RB1, P107, P130, WT1, TP53, NF1, NF2, VHL, APC, NB1, MLM, MEN1, BCNS, RCC, BRCA1, BRCA2, DCC, MTS1=p16, MTS 2, p21, p27 and others. In a preferred embodiment, the component (A) comprises a section of RB1, in particular amino acids 649-654 of RB1, i.e. LFYKKV or is hydrophatically homologous thereto.

The component (B) of the fusion peptide has the property of stabilizing said component (A) as a cofactor so that the latter is not proteolytically degraded in the cell. This may be achieved by the peptides of the present invention rapidly arriving at the cell nucleus where they are less prone to proteolytic degradation (R. Fahraeus et al., Current Biology 1996, vol.6, no. 1, pp. 84-91) or by using branched components (B) such as polylysine branches or polylysine cores or by using D-amino acids. In a preferred embodiment, the component (B) is a polylysine core (R. Radulescu et al., Biochemical and Biophysical Research Communications, 1995, vol. 206, pp. 97-102; and G. Fassina, EPO 0 481 930 A2) or a nuclear localization sequence (NLS), particularly a SV40 NLS or Penetratin or a bipartite NLS or the RNP A1 NLS (M9 region). For the construction of peptides which are preferably directed to the cell nucleus general reference is made to Sheldon et al., Proc. Natl. Acad. Sci. USA, vol. 92, pp. 2056-2060 (1995); Dingwall et al., Trends in Biochemical Sciences 16, pp. 478-481 (1991), M.S. Moore, Current Biology, vol. 6, no. 2, pp. 137-140 (1996); D.A. Jans, FASEB Journal, 1994, vol 8, pp. 841-847; J. Moroianu & J.F. Riordan PNAS, 1994, vol. 91, pp. 1677-1681 and D.Derossi et al., Journal of Biological Chemistry, 1994, vol. 269, pp. 10444-10450.

In a preferred embodiment, the component (A) has the following sequence or is homologous thereto in at least two positions:

NH₂-LFYKKV-COOH

(P1)



$\text{NH}_2\text{-dLdFdYdKdKdV-COOH}$ (P4)

$\text{NH}_2\text{-KVLVFKRQIKIWFQNRRMKWKK-COOH}$ (P8)

(the lines indicate a hydrophobic homology)

From the above the following preferred peptides according to the present invention may be derived:

$\text{NH}_2\text{-[LFYKKVGGG]}_4\text{-[KRG]}_2\text{-KG-COOH}$ (P2)

This peptide is a combination of the sequence P1 and the polylysine core $[\text{GGG}]_4\text{-[KRG]}_2\text{KG}$

$\text{NH}_2\text{-[LFYKKVGGG]}_4\text{-[K]}_2\text{-KG-COOH}$ (P2i)

This peptide is a combination of the sequence P1 and the polylysine core $[\text{GGG}]_4\text{-[K]}_2\text{-KG}$.

$\text{NH}_2\text{-[dLdFdYdKdKdV-GGG]}_4\text{-[IKdRG]}_2\text{-IKG-COOH}$ (P3)

This peptide is a combination of the sequence P4 and the polylysine core $[\text{GGG}]_4\text{-[IKdRG]}_2\text{-IKG}$.

$\text{NH}_2\text{-[dLdFdYdKdKdVGGG]}_4\text{-[IK]}_2\text{-IKG-COOH}$ (P3i)

This peptide is a combination of the sequence P4 and the polylysine core $[\text{GGG}]_4\text{-[IK]}_2\text{-IKG}$.


$\text{NH}_2\text{-LFYKKVPKKRKV-COOH}$ (P5)

This peptide P5 is composed of the sequence P1 and the nuclear localization sequence of the large T antigen of the SV40 virus.


$\text{NH}_2\text{-LFYKKVRQIKIWFQNRRMKWKK-COOH}$ (P6)

This peptide P6 is a combination of the sequence P1 and Penetratin, a sequence consisting of 16 amino acids located within the Antennapedia homeodomain, which sequence mediates translocation across membranes and thus also nuclear localization.





This peptide P7s is a combination of the sequence dKdVdLdYdFdK which is hydrophatically homologous to P1 and the polylysine core [GGG]₄-[IKdRG]₂-IKG.



This peptide P7 is a combination of the sequence dKdVdLdYdFdK which is hydrophatically homologous to P1 and the polylysine core [GGG]₄-[IK]₂-IKG.



This peptide P8 is a combination of the sequence dKdVdLdYdFdK which is hydrophatically homologous to P1 and Penetratin.

"D" and "L" specify the configuration of the amino acids that are shown in the one-letter code.

The peptides of the present invention normally comprise L- and/or D-amino acids. According to the present invention the all-L-forms, the all-D-forms, the retro-inverse isomers and the corresponding permutations of the L- and D-form of each amino acid are within the scope. Moreover, according to the present invention all permutations of the oxidized and reduced forms of each amino acid and amino acids both in the free form and bearing protective groups are within the scope. The most effective concentration of the peptides according to the present invention is in the range of from 10^{-4} to 10^{-5} M, with other effective concentrations being also possible depending on the specific application. As far as branched peptides are concerned, it has been shown to be advantageous that they are present in the all-D form. It is assumed that linear peptides containing an NLS enter the cell nucleus; branched peptides are likely to enter the cell nucleus, but they may also be effective outside the nucleus.

The peptides according to the present invention may be designated "SCAPs", i.e. "Synthetic Cofactor-associated Anti-oncogenic Peptides".

The preparation of the peptides according to the present invention is preferably performed according to the common solid-phase method (see G. A. Grant, "Synthetic Peptides", W.H. Freeman and Company, New York, 1992). The subsequent purification



of the peptides according to the present invention is carried out and is verified as described ((R. Radulescu et al., Biochemical and Biophysical Research Communications 1995, vol. 206, pp. 97-102). The latter reference also provides an example for using the peptides of the present invention for the biotechnological purification of growth factors, e.g. insulin, and growth factor receptors. In order to biotechnologically isolate growth factors and growth factor receptors, the peptides according to the present invention that carry an NLS could be coupled to a chromatography column comprising a heparan sulfate matrix.

The components (A) and (B) of the peptides according to the present invention may also be cleaved from the corresponding proteins and connected with each other according to standard methods. Additional techniques for the preparation of the peptides are within the ordinary skill (see G.A. Grant, "Synthetic Peptides", W.H. Freeman and Company, New York, 1992).

The invention further relates to DNA/RNA coding for the peptides according to the present invention with the DNA/RNA sequence being derived from the genetic code.

In a preferred embodiment, the following DNA/RNA sequence codes for the above mentioned amino acid sequences (P1) and (P4) that represent component (A) of the peptide according to the present invention:

5' - CUU UUC UAC AAG AAG GUU - 3' (D1)

In a further preferred embodiment, the following DNA/RNA sequence codes for the above mentioned peptide (P5) according to the present invention:

5'-CUU UUC UAC AAG AAG GUU CCU AAG AAG AAG
CGU AAG GUU-3' (D5)

In a preferred embodiment, the following DNA/RNA sequence codes for the above mentioned peptide (P6) according to the present invention

5'-CUU UUC UAC AAG AAG GUU CGU CAA AUA AAG
AUA UGG UUC CAA AAU CGU CGU AUG AAG UGG
AAG AAG- 3' (D6)



In a preferred embodiment, the following DNA/RNA sequence codes for the above mentioned peptide (P8):

5'-AAG GUU CUU UAC UUC AAG CGU CAA AUA AAG
 AUA UGG UUC CAA AAU CGU CGU AUG AAG UGG
 AAG AAG-3' (D8)

The DNA/RNA sequences coding for the peptides of the present invention may be incorporated into adequate vectors for use in the gene therapy of cancer. A survey of the methodology is to be found in R.C.Mulligan, Science 1993, vol. 260, pp. 926-932.

The above DNA/RNA sequences comprise DNA/RNA sequences hybridizing thereto under stringent conditions, as known to those skilled in the art. These are in particular DNA/RNA sequences that hybridize with the above DNA/RNA sequences at about 20 °C below the melting point of DNA/RNA. Moreover, the above mentioned DNA/RNA sequences comprise DNA/RNA sequences that are related to the above mentioned DNA/RNA sequences according to the degeneracy of the genetic code.

The present invention may also be applied in bioinformatics and molecular biology. The following strategy could be applied to identify tumor suppressor proteins that interact with a growth factor or its receptor. The cDNA of the corresponding growth factor or its receptor, respectively, could be derived from the NCBI data base and this cDNA may be translated according to the complementary peptide strategy into a complementary DNA and into a peptide by means of the DNA Strider software. For the resulting complementary peptides homologous proteins/peptides may be found (the sought tumor suppressors) by means of the BLAST algorithm in the OWL data base navigator. On the other hand, it is possible to start with the tumor suppressor cDNA and look in an analogous manner for growth factors or their receptors, respectively, as interacting partners. This method could accelerate and facilitate the cloning of (novel) tumor suppressor proteins or (novel) growth factors or growth factor receptors, respectively. By way of example, the cDNA of the human EGF precursor has been copied from the NCBI data base and copied into the DNA Strider software. By means of said software the complementary DNA sequence(s) has/have been derived from the EGF precursor cDNA and this DNA sequence(s) has/have been translated into peptides, into so-called peptides complementary to the EGF precursor protein. Subsequently, by means of the BLAST algorithm in the OWL data base navigator peptides/proteins were searched for that are homologous to these complementary peptides. As a result, several nuclear proteins were revealed to be homologous to the EGF precursor, for instance the p130 protein that is



structurally and functionally related to RB1, in particular the amino acids 290-313 of p130. More specifically, if the regions are aligned in an anti-parallel fashion to each other, the amino acids of the EGF precursor 209-213 (REGSN) and the amino acids 305-309 of p130 (IGTLS) are hydropathically complementary to each other and are therefore potential binding sites in the assumed complex between the EGF precursor and p130. Thus, the amino acid sequence IGTLS or sequences that are hydropathically homologous thereto may represent component (A) of an antiproliferative peptide of the present invention (see claims 1 and 2).

As far as therapeutic applications are concerned, the peptides of the present invention are used in a pharmaceutical composition either alone or together with several common adjuvants, fillers and/or additives. A particularly advantageous embodiment is the combination of the above mentioned peptides P3 and P6 as well as of P3 and P5, respectively. As far as the form of administration of the pharmaceutical composition is concerned, the following is appropriate: ointments, solutions, dispersions, emulsions, aerosols, foams, particulate matter (for example granulates, agglomerates, powder, micropearls, adsorbates), pills, pastilles, tablets, dragées or capsules. The peptides of the present invention may also be used together with cytostatic remedies or in combination with radiation treatments. The peptides are preferably administered locally, intracutaneously or transcutaneously, for systemic administration preferably intravenously, intraarterially, orally and rectally. The administration into cavities is preferably carried out intrathecally, intraperitoneally or intracavitarily.

The peptides, DNA/RNA sequences and pharmaceutical compositions according to the present invention are useful as drugs for treating cancer and are applied according to the present invention in this manner, displaying a marked cytotoxic effect.

A particular effectiveness is seen against breast cancer cells, osteosarcoma cells and leukemia cells. Due to the underlying concept, the peptide according to the present invention generally acts on all tumor cells that display a defective retinoblastoma gene or protein, respectively.

The invention will be described with reference to the 15 figures and to tables, wherein:

Fig. 1 to Fig. 12 shows the % cell population of MCF-7 cells or SAOS-2 cells in the G1-, S- and G2/M phase in the presence or absence of different peptides of the present invention;



Fig. 13 shows the cytotoxic effect of the peptide P3 on K562 cells;

Fig. 14 shows the cytotoxic effect of peptide P3 on CCRF-CEM cells and CCRF-CEM/ACT 400 cells;

Fig. 15 shows the effect of peptide P3 on normal peripheral blood mononuclear cells;

Table 1 shows the P5- and P6-mediated inhibition of the cell cycle progression in MCF-7 cells which, by contrast, is not achieved with Penetratin;

Table 2 shows the P5- and P6-mediated inhibition of the cell cycle progression in SAOS-2 cells which, by contrast, is not achieved with Penetratin.

Figure 1 shows that, under serum-free conditions, the peptide P3 of the present invention at a concentration of 10^{-5} M reduces the G1 phase and increases the S phase in MCF-7 cells that have been synchronized in the G0/G1 phase. The morphology of the cells treated with P3 corresponds to that of apoptotic cells.

Figure 2 shows that the peptide P3 of the present invention at a concentration of 10^{-5} M results in an increase of the G1 and G2/M phases as well as in a decrease of the S phase in MCF-7 cells that have been stimulated by insulin-like growth factor 1 (IGF-1) at an optimal concentration of 10^{-8} M. Accordingly, P3 blocks the effect of IGF-1 on MCF-7 cells. In particular, P3 delays the progression of the cell cycle caused by IGF-1 and thus delays cell division. The morphology of the cells treated with P3 corresponds to that of apoptotic cells.

Figure 3 shows that, under serum-free conditions, each of the peptides P4, P5 and P6 at a concentration of 10^{-5} M reduces the G1 phase and increases the S phase in MCF-7 cells that have been synchronized in the G0/G1 phase. The morphology of said cells, in particular of those treated with P6, corresponds to that of apoptotic cells.

Figure 4 shows that the peptide P6 of the present invention at a concentration of 10^{-5} M increases the G1 phase as well as decreases the S phase in MCF-7 cells that have been stimulated with IGF-1 at an optimal concentration of 10^{-8} M. Therefore, P6 blocks the effect of IGF-1 on MCF-7 cells. In particular, P6 delays the progression of the cell cycle caused by IGF-1 and thus delays cell division. The morphology of the cells treated with P6 corresponds to that of apoptotic cells.



Figure 5 shows that the combination of the peptides P3 and P5 at a concentration of 10^{-5} M each as well as the combination of P3 and P6 at a concentration of 10^{-5} M each results in an increase of the G1 phase and the G2/M phase as well as in a decrease of the S phase in MCF-7 cells that have been stimulated by 10 % fetal calf serum (FCS). The morphology of the cells treated with these combinations of peptides corresponds to that of apoptotic cells.

Figure 6 shows that the peptide P3 of the present invention at a concentration of 10^{-5} M increases the G1- and the G2 phases as well as decreases the S phase in MCF-7 cells that have been stimulated by estradiol (E2) at an optimal concentration of 10^{-9} M or by epidermal growth factor (EGF) at an optimal concentration of 10^{-8} M. The morphology of the cells treated with P3 corresponds to that of apoptotic cells.

Figure 7 shows that the peptide P3 of the present invention blocks the progression of the cell cycle that is caused by IGF-1 [10^{-8} M] in a dose-dependent manner. The morphology of the cells treated with P3 [5×10^{-6} M] and in particular of the cells treated with P3 [10^{-5} M] each corresponds to that of apoptotic cells.

Figure 8 shows that, under serum-free conditions, the peptide P3 [10^{-5} M] of the present invention reduces the G1 phase and increases the S and G2/M phases in SAOS-2 cells that have been synchronized in the G0/G1 phase. The morphology of the cells treated with P3 corresponds to that of apoptotic cells.

Figure 9 shows that the peptide P3 [10^{-5} M] increases the G1 phase and decreases the S phase in SAOS-2 cells that have been stimulated by 10 % FCS. The morphology of the cells treated with P3 corresponds to that of apoptotic cells.

Figure 10 shows that the peptide P3 [10^{-5} M] according to the present invention reduces the G1 phase and increases the S phase of asynchronously growing MCF-7 cells that have been incubated in DMEM cell culture medium containing 10 % FCS. The morphology of said cells treated with P3 corresponds to that of apoptotic cells.

Figure 11 shows that the peptide P8 [10^{-5} M] of the present invention increases the G1 phase and the G2/M phase as well as decreases the S phase in MCF-7 cells that have been stimulated by IGF-1 at an optimal concentration of 10^{-8} M. Accordingly, P8 blocks the effect of IGF-1 on MCF-7 cells. In particular, P8 delays the progression of the cell cycle caused by IGF-1 and thus delays cell division. The morphology of said cells treated with P8 corresponds to that of apoptotic cells.



Figure 12 shows that the peptide P7s [10^{-5} M] of the present invention increases the G1 phase and the G2/M phase as well as decreases the S phase in MCF-7 cells that have been stimulated by IGF-1 at an optimal concentration of 10^{-8} M. Accordingly, P7s blocks the effect of IGF-1 on MCF-7 cells. In particular, P7s delays the progression of the cell cycle caused by IGF-1 and thus delays cell division. The morphology of said cells treated with P7s corresponds to that of apoptotic cells.

Figure 13 shows the cytotoxic effect of the peptide P3 [10^{-5} M] of the present invention on asynchronously growing K562 cells incubated in RPMI cell culture medium to be time-dependent. The results have been plotted as the living cells treated with P3 being a percentage of the living cells not treated with P3. The number of the living cells has been determined by counting at least 200 cells at each time point according to the trypan blue method.

Figure 14 shows the peptide according to the present invention P3 [10^{-5} M] to act in a cytotoxic manner on asynchronously growing CCRF-CEM_{sensitive} cells and CCRF-CEM/ACT 400_{resistant} cells that have been incubated in a RPMI culture medium containing 10 % FCS.

The Fig. 15 shows the peptide P3 of the present invention [10^{-5} M] to have no effect on normal human peripheral blood mononuclear cells, irrespective of whether they are in a quiescent (a) state or in an activated (b) state. Accordingly, the cells treated with P3 do not show any morphological changes. The incubation of cells with P3 was performed for a time period of 24 hours.

Table 1 shows that the peptides P5 and P6 of the present invention each at a concentration of 10^{-5} M reduce the S phase in MCF-7 cells that have been stimulated by IGF-1 [10^{-8} M] or insulin [10^{-6} M], respectively. The peptide Penetratin [10^{-5} M] did not show any effect, as expected.

Table 2 shows that the peptides P5 and P6 of the present invention at a concentration of 5×10^{-5} M each results in an increase of the G1 phase and a decrease of the S phase in SAOS-2 cells that have been stimulated by 10 % FCS.

Taken together, based on figures 1 to 15 and tables 1 and 2, it may be ascertained that the peptides P3, P5, P6, P7s or P8 of the present invention alone and/or in combination have the property of considerably delaying the progression of the cell cycle and thus the



cell division of the MCF-7 breast cancer cells, of the SAOS-2 osteosarcoma cells or of leukemia cells (K562, CCRF-CEM_{sensitive}, CCRF-CEM/ACT 400_{resistant}) under particular conditions of cell culture. The data shown for IGF-1 [10^{-8} M] also apply to insulin [10^{-6} M].

As a result, these peptides have the potential to also be effective antineoplastic agents against the growth of cancer in vivo in human beings.

The invention is now illustrated by way of the following examples:

Examples

The experimental setting comprises experiments with the breast cancer cell line MCF-7 containing an intact retinoblastoma protein and the human osteosarcoma cell line SAOS-2 containing a defective retinoblastoma protein. Cells are seeded in 12-well plates at 100000 (= one hundred thousand) cells/well/ml in RPMI medium or DMEM medium containing 10 % FCS and allowed to adhere for 24 hours. Subsequently, the cells are starved by incubation for 3 days in DMEM without FCS, such that they are synchronized in the G0/G1 phase and then the cells are stimulated by 10 % FCS or 10^{-8} M IGF-1 or 10^{-6} M insulin, respectively, for 24 hours. The effect of each of the added peptides on each of the above modes of stimulation, which effect reflects the rate of cell division, is investigated. The control (cells synchronized in G0/G1) is fixed at time 0 after three days of starvation. The remaining cells (+/- peptide) are fixed after 24 hours. The cells are subsequently analyzed by FACS for their cell cycle distribution. Analogous methods are to be found e.g. in R. Fahraeus et al., *Current Biology*, 1996, vol. 6, no. 1, pp. 84-91 and L. Zhu et al., *Genes & Development*, 1993, vol. 7, pp. 1111-1125.

The second experimental setting relates to the leukemia cell lines K562 and CCRF-CEM and CCRF-CEM/ACT400. 100000 asynchronously growing cells/well/ml RPMI/10 % FCS have each been incubated for 48 hours with each of the peptides in 6-well plates. As a readout, the number of dead cells / 200 counted cells is determined according to the trypan blue method (L.D. Attardi et al., *The EMBO Journal*, 1996, vol. 15, no. 14, pp. 3693-3701 and M.K. Reeder & H.C. Isom, *Cell Growth & Differentiation* 1996, vol. 7, pp. 449-460) after this 48-hour incubation. The more dead cells, the more cytotoxic the peptide and thus the more effective the peptide.

The results of the examples are illustrated in the figures 1 to 15 and in the tables 1 and 2.



- 12a -

Throughout this specification, unless the context requires otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element or integer or group of elements or integers but not the exclusion of any other element or integer or group of elements or integers.

- 5 Reference to any prior art in this specification is not, and should not be taken as, an acknowledgment or any form of suggestion that this prior art forms part of the common general knowledge in Australia or any other country.

5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2160
2161
2162
2163
2164
2165
2166
2167
2168
2169
2170
2171
2172
2173
2174
2175
2176
2177
2178
2179
2180
2181
2182
2183
2184
2185
2186
2187
2188
2189
2190
2191
2192
2193
2194
2195
2196
2197
2198
2199
22



TAB. 1

TAB. 1/2

| | Control | IGF-I | P5 + IGF-I | P6 + IGF-I | Penetratin + IGF-I |
|-------|---------|-------|------------|------------|--------------------|
| G1: | 70,2 | 47,3 | 54,0 | 53,7 | 50,5 |
| S: | 17,7 | 45,4 | 32,4 | 27,7 | 39,3 |
| G2/M: | 12,1 | 7,3 | 13,6 | 18,6 | 10,1 |

| | Control | Insulin | P6 + Insulin | Penetratin + Insulin |
|-------|---------|---------|--------------|----------------------|
| G1: | 70,2 | 38,3 | 48,7 | 39,6 |
| S: | 17,7 | 52,8 | 36,6 | 49,6 |
| G2/M: | 12,1 | 8,9 | 14,6 | 10,9 |



TAB. 2/2

TAB. 2

| | Control | FCS | P5 + FCS | P6 + FCS | Penetratin + FCS |
|-------|---------|------|----------|----------|------------------|
| G1: | 79,6 | 63,1 | 73,5 | 76,6 | 62,3 |
| S: | 12,0 | 32,5 | 13,2 | 12,2 | 29,9 |
| G2/M: | 8,4 | 4,4 | 13,3 | 11,2 | 7,8 |
| | | | | | 14 |

CLAIMS

1. Antiproliferative peptide AB or BA, consisting of :
 - an antiproliferative component (A), comprising a fragment of a tumor suppressor protein or a peptide segment hydropathically homologous thereto, which binds to a growth factor segment or a growth factor receptor segment,
 - a component (B), which as co-factor stabilises said component (A) against proteases, provided that the assembly L-F-Y-K-K-V-G-G-G]₄ - [K]₂ - K-G be excluded.
2. Peptide in accordance with Claim 1,
where said antiproliferative component (A) is hydropathically complementary to a growth factor segment or a growth factor receptor segment.
3. Peptide in accordance with Claim 1 or 2,
where said antiproliferative component (A) is a tumor suppressor protein fragment derived from the retinoblastoma protein (Rb).
4. Peptide in accordance with Claims 1 to 3,
where the component (A) comprises the amino acid sequence F-Y-K-K or an amino acid sequence which is hydropathically homologous thereto in at least two positions.
5. Peptide in accordance with Claim 4,
where the component (A) comprises the amino acid sequence L-F-Y-K-K-V or an amino acid sequence hydropathically homologous thereto in at least two positions.



6. Peptide in accordance with one of the preceding Claims,
where said component (B) is selected from a branched peptide, a polylysine core, D-amino acids or a nuclear localisation sequence (NLS).
7. Peptide in accordance with Claim 6,
- 5 where said component (B) is a polylysine core, which is selected from
 - a) [K-R-G]₂-K-G
 - b) [K]₂-K-G
 - c) [IK-dR-G]₂-IK-G
8. Peptide in accordance with Claim 6,
- 10 where said component (B) is a NLS selected from
 - a) P-K-K-K-R-K-V
 - b) R-Q-I-K-I-W-F-Q-N-R-R-M-K-W-K-K
 - c) bipartite NLS
 - d) RNP A1 NLS
- 15 9. Peptide in accordance with one of the preceding Claims,
where the peptide is selected from
 - a) [L-F-Y-K-K-V-G-G-G]₄-[K-R-G]₂-K-G
 - b) [dL-dF-dY-dK-dK-dV-G-G-G]₄-[IK-dR-G]₂-IK-G
 - c) [dL-dF-dY-dK-dK-dV-G-G-G]₄-[K]₂-IK-G
 - 20 d) L-F-Y-K-K-V-P-K-K-K-R-K-V
 - e) (all-D) L-F-Y-K-K-V-P-K-K-K-R-K-V
 - f) L-F-Y-K-K-V-R-Q-I-K-I-W-F-Q-N-R-R-M-K-W-K-K



- g) (all-D) L-F-Y-K-K-V-R-Q-I-K-I-W-F-Q-N-R-R-M-K-W-K-K
- h) [dK-dV-dL-dY-dF-dK-G-G-G]₄-[K-dR-G]₂-IK-G
- i) [dK-dV-dL-dY-dF-dK-G-G-G]₄-[IK]₂-IK-G
- j) K-V-L-Y-F-K-R-Q-I-K-I-W-F-Q-N-R-R-M-K-W-K-K
- 5 k) (all-D) K-V-L-Y-F-K-R-Q-I-K-I-W-F-Q-N-R-R-M-K-W-K-K
10. Peptide in accordance with one of the preceding Claims,
where the growth factor segment or the growth factor receptor segment is
an amino acid sequence with the hydropathic profile hydrophobic amino
acid - X - hydrophobic amino acid - X - hydrophilic amino acid, wherein X
10 is any amino acid.
11. Peptide in accordance with Claim 10, where the growth factor segment or
the growth factor receptor segment comprises the amino acid sequence
L-X-C-X-E or F-V-C-G-D, where X is any amino acid.
12. Peptide in accordance with Claim 11, where the amino acid sequence
15 L-X-C-X-E is derived from insulin.
13. Nucleic acid coding for a peptide in accordance with one of the preceding
Claims, corresponding with the genetic code.
14. Nucleic acid in accordance with Claim 13, where the nucleic acid comprises
the following sequence:
20 a) 5' - UUC UAC AAG AAG - 3' (D0)
- or a nucleic acid coding for the same peptide,
- b) wherein one or a plurality of nucleotides are replaced, or



- c) which hybridises with the nucleic acid (D0), or
 - d) which is related to the nucleic acid (D0) via the degenerated genetic code.
15. Nucleic acid in accordance with Claim 13, where the nucleic acid comprises the following sequence:
- 5 a) 5' - CUU UUC UAC AAG AAG GUU - 3' (DI)
- or a nucleic acid coding for the same peptide,
- b) wherein a plurality of nucleotides are replaced, or
 - c) which hybridises with the nucleic acid (DI) , or
 - d) which is related to the nucleic acid (DI) via the degenerated genetic code.
- 10 16. Peptide nucleic acid, which is structurally homologous to a nucleic acid according to one of Claims 13 to 15.
17. Pharmaceutical composition, which contains one or a plurality of peptides according to one of Claims 1 to 12.
18. Pharmaceutical composition in accordance with Claim 17 in the form of
- 15 ointments, solutions, dispersions, emulsions, aerosols, foams, particulate matter, pills, pastilles, tablets, dragees or capsules.
19. Pharmaceutical composition in accordance with Claim 17,
- where the particulate matter is selected from granulates, agglomerates, powder, micropearls or adsorbates.
- 20 20. Application of a peptide in accordance with one of Claims 1 to 12 for the diagnosis and/or therapy of diseases, which are characterised by increased proliferation or hyperproliferation of cells.



- 19 -

21. Application of a nucleic acid in accordance with one of Claims 13 to 15 for the diagnosis and/or therapy of diseases which are characterised by increased proliferation or hyperproliferation of cells.
22. Application of a peptide nucleic acid in accordance with Claim 16 for the diagnosis and/or therapy of diseases which are characterised by increased proliferation or hyperproliferation of cells.
23. Application in accordance with one of the Claims 20 to 22, where the disease is a benign or malignant tumor or atherosclerosis.
24. An anti-proliferative peptide according to any one of Claims 1-12 or a nucleic acid according to any one of Claims 13-15 or a peptide nucleic acid according to Claim 16 or a pharmaceutical composition according to any one of Claims 17-19 or an application according to any one of Claims 20-23 substantially as hereinbefore defined with reference to the Figures and/or Examples.

5
10



1/15




FIG.1




FIG. 2




FIG. 3

4 / 15




FIG. 4

5/15




FIG. 5

6/15




FIG. 6




FIG. 7




FIG. 8

9 / 15




FIG. 9

10 / 15




FIG. 10




FIG. 11




FIG. 12

13 / 15





FIG. 13

14 / 15

b) CCRF - CEM / ACT 400



LEGENDE

- Kontrolle : ●
- P3 : ⊗
- P6 : ○
- P8 : ⊖

a) CCRF - CEM




FIG.14

15/15




FIG. 15

FIG. 16


Dose dependency of peptide cytotoxicity towards KS62 human leukemic cells

FIG. 17

